Sign In
Buy MITO
$0.320
+0 (+0%)
At Close: Feb 14, 2023
Stealth BioTherapeutics Corp (NASDAQ:MITO) Given Consensus Rating of "Buy" by Brokerages
10:46am, Sunday, 23'rd Feb 2020
Shares of Stealth BioTherapeutics Corp (NASDAQ:MITO) have been given an average recommendation of “Buy” by the eight brokerages that are covering the stock, Marketbeat Ratings reports. Three equit
The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study
12:06pm, Thursday, 20'th Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia
Stealth BioTherapeutics (NASDAQ:MITO) Rating Reiterated by Cantor Fitzgerald
09:46pm, Tuesday, 18'th Feb 2020
Stealth BioTherapeutics (NASDAQ:MITO)‘s stock had its “overweight” rating restated by Cantor Fitzgerald in a research note issued on Tuesday, The Fly reports. They currently have a $10.00 target
TSLA, KR among premarket gainers
02:15pm, Tuesday, 18'th Feb 2020
Bellerophon Therapeutics (NASDAQ:BLPH) +67% on positive top-line data from a recently completed acute, intra-patient, dose escalation, hemodynamics study of INOpulse for the treatment of Pulmonary Hy
Stealth Bio up 34% premarket on "positive" elamipretide data
01:26pm, Tuesday, 18'th Feb 2020
Thinly traded nano cap Stealth BioTherapeutics (NASDAQ:MITO) is up 34% premarket on increased volume in reaction to positive results from a retrospective natural history study assessing the efficacy
35 Healthcare Stocks Moving In Tuesday's Pre-Market Session
01:25pm, Tuesday, 18'th Feb 2020
Gainers
Stealth BioTherapeutics, Inc. (NASDAQ: MITO) stock increased by 38.4% to $3.10 during Tuesday's pre-market session. According to the most recent rating by H...
Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfu
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL
The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data
02:18pm, Wednesday, 12'th Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NAS
Analysts Anticipate Stealth BioTherapeutics Corp (NASDAQ:MITO) Will Post Earnings of -$0.04 Per Share
07:18am, Friday, 07'th Feb 2020
Equities research analysts expect that Stealth BioTherapeutics Corp (NASDAQ:MITO) will announce earnings per share (EPS) of ($0.04) for the current fiscal quarter, according to Zacks Investment Resear
The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data
12:43pm, Wednesday, 05'th Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 4) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (N
The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics
12:12pm, Tuesday, 28'th Jan 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ: TXG ) Achillion Pharmace
Stealth BioTherapeutics Initiates First-in-Human Study of SBT-272
12:30pm, Tuesday, 21'st Jan 2020
Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfu
In wake of drug trial fail, Newton firm cuts most staff, top scientist quits
11:20am, Thursday, 09'th Jan 2020
A Newton biotech startup is making major changes after a late-stage drug trial failure, announcing this week that it has laid off 60% of its staff.
4 Reasons Why Investors Should Buy Alexion (ALXN) in 2020
02:49pm, Thursday, 02'nd Jan 2020
Alexion's (ALXN) growth prospects look strong for 2020 as Soliris maintains momentum and Ultomiris gains further traction.
